J Menopausal Med.  2019 Aug;25(2):83-87. 10.6118/jmm.19192.

Sleep Disorders and Menopause

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea. mrkim@catholic.ac.kr

Abstract

Sleep disorders are one of the main symptoms of menopause. Symptoms of sleep disorders that menopausal women complain about include falling asleep, frequent awakening and/or early morning awakening. There are many possible causes of sleep disorders in postmenopausal women, including vasomotor symptoms, ovarian hormone changes, restless legs syndrome, periodic leg movement syndrome, and obstructive sleep apnea. In this review, we discuss the relationship between menopause and sleep disorders.

Keyword

Menopause; Postmenopause; Sleep wake disorders

MeSH Terms

Accidental Falls
Female
Humans
Leg
Menopause*
Postmenopause
Restless Legs Syndrome
Sleep Apnea, Obstructive
Sleep Wake Disorders*

Reference

1. Miller EH. Women and insomnia. Clin Cornerstone. 2004; 6 Suppl 1B:S8–S18.
Article
2. Freedman RR. Postmenopausal physiological changes. Curr Top Behav Neurosci. 2014; 21:245–256.
Article
3. Twiss JJ, Wegner J, Hunter M, Kelsay M, Rathe-Hart M, Salado W. Perimenopausal symptoms, quality of life, and health behaviors in users and nonusers of hormone therapy. J Am Acad Nurse Pract. 2007; 19:602–613.
Article
4. Weber MT, Rubin LH, Maki PM. Cognition in perimenopause: the effect of transition stage. Menopause. 2013; 20:511–517.
5. Schmidt PJ. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med. 2005; 118 Suppl 12B:54–58.
Article
6. Sang JH, Kim TH, Kim SA. Flibanserin for treating hypoactive sexual desire disorder. J Menopausal Med. 2016; 22:9–13.
Article
7. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011; 38:567–586.
Article
8. Chokroverty S. Overview of sleep & sleep disorders. Indian J Med Res. 2010; 131:126–140.
9. Guidozzi F. Sleep and sleep disorders in menopausal women. Climacteric. 2013; 16:214–219.
Article
10. Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014; 101:905–915.
Article
11. Abdi F, Mobedi H, Roozbeh N. Hops for menopausal vasomotor symptoms: mechanisms of action. J Menopausal Med. 2016; 22:62–64.
Article
12. Lampio L, Polo-Kantola P, Polo O, Kauko T, Aittokallio J, Saaresranta T. Sleep in midlife women: effects of menopause, vasomotor symptoms, and depressive symptoms. Menopause. 2014; 21:1217–1224.
13. Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, Polo O. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril. 1999; 71:873–880.
Article
14. Young T, Rabago D, Zgierska A, Austin D, Laurel F. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. Sleep. 2003; 26:667–672.
Article
15. Manber R, Armitage R. Sex, steroids, and sleep: a review. Sleep. 1999; 22:540–555.
16. Empson JA, Purdie DW. Effects of sex steroids on sleep. Ann Med. 1999; 31:141–145.
Article
17. Polo-Kantola P. Dealing with menopausal sleep disturbances. Sleep Med Clin. 2008; 3:121–131.
Article
18. Scharf MB, McDannold MD, Stover R, Zaretsky N, Berkowitz DV. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clin Ther. 1997; 19:304–311.
Article
19. Freedman RR, Woodward S. Core body temperature during menopausal hot flushes. Fertil Steril. 1996; 65:1141–1144.
20. Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med. 2005; 1:291–300.
Article
21. Grigoriadis S, Kennedy SH. Role of estrogen in the treatment of depression. Am J Ther. 2002; 9:503–509.
Article
22. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ. 2008; 337:a1190.
Article
23. Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002; 100:1209–1218.
Article
24. Okatani Y, Morioka N, Wakatsuki A. Changes in nocturnal melatonin secretion in perimenopausal women: correlation with endogenous estrogen concentrations. J Pineal Res. 2000; 28:111–118.
Article
25. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012; 13:895–905.
Article
26. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007; 16:372–380.
27. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005; 48:301–310.
Article
28. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009; 15:32–51.
29. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009; 26:613–626.
Article
30. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008; 58:1–10.
Article
31. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003; 306:954–964.
Article
32. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2004; 26:1578–1586.
Article
33. Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012; 16:283–295.
Article
34. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006; 108:1402–1410.
35. Srinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP, Brown GM. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedativehypnotics? Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35:913–923.
Article
36. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014; 57:3161–3185.
37. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006; 16:93–100.
Article
38. Innes KE, Selfe TK, Agarwal P. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 2011; 12:623–634.
Article
39. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012; 21:1503–1522.
Article
40. Manconi M, Ulfberg J, Berger K, Ghorayeb I, Wesström J, Fulda S, et al. When gender matters: restless legs syndrome. Report of the “RLS and woman” workshop endorsed by the European RLS Study Group. Sleep Med Rev. 2012; 16:297–307.
Article
41. Parry BL, Fernando Martínez L, Maurer EL, López AM, Sorenson D, Meliska CJ. Sleep, rhythms and women's mood. Part II Menopause. Sleep Med Rev. 2006; 10:197–208.
Article
42. Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, et al. Associations between anxiety, depression and insomnia in peri- and post-menopausal women. Maturitas. 2012; 72:61–65.
Article
43. Dancey DR, Hanly PJ, Soong C, Lee B, Hoffstein V. Impact of menopause on the prevalence and severity of sleep apnea. Chest. 2001; 120:151–155.
Article
44. Resta O, Bonfitto P, Sabato R, De Pergola G, Barbaro MP. Prevalence of obstructive sleep apnoea in a sample of obese women: effect of menopause. Diabetes Nutr Metab. 2004; 17:296–303.
45. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause. 2006; 13:280–285.
Article
46. Resta O, Caratozzolo G, Pannacciulli N, Stefàno A, Giliberti T, Carpagnano GE, et al. Gender, age and menopause effects on the prevalence and the characteristics of obstructive sleep apnea in obesity. Eur J Clin Invest. 2003; 33:1084–1089.
Article
47. Vorona RD, Winn MP, Babineau TW, Eng BP, Feldman HR, Ware JC. Overweight and obese patients in a primary care population report less sleep than patients with a normal body mass index. Arch Intern Med. 2005; 165:25–30.
Article
48. Bass J, Turek FW. Sleepless in America: a pathway to obesity and the metabolic syndrome? Arch Intern Med. 2005; 165:15–16.
49. Phillips BA, Collop NA, Drake C, Consens F, Vgontzas AN, Weaver TE. Sleep disorders and medical conditions in women. Proceedings of the Women & Sleep Workshop, National Sleep Foundation, Washington, DC, March 5–6, 2007. J Womens Health (Larchmt). 2008; 17:1191–1199.
50. Manber R, Kuo TF, Cataldo N, Colrain IM. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep. 2003; 26:163–168.
51. Shahar E, Redline S, Young T, Boland LL, Baldwin CM, Nieto FJ, et al. Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med. 2003; 167:1186–1192.
Article
52. Nowakowski S, Meliska CJ, Martinez LF, Parry BL. Sleep and menopause. Curr Neurol Neurosci Rep. 2009; 9:165–172.
Article
53. Phillips B. Movement disorders: a sleep specialist's perspective. Neurology. 2004; 62:S9–S16.
Article
54. Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D. High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study. J Clin Sleep Med. 2010; 6:423–427.
Article
55. Littner MR, Kushida C, Anderson WM, Bailey D, Berry RB, Hirshkowitz M, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004; 27:557–559.
Article
Full Text Links
  • JMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr